litlas
Log inCreate account

Egbert F. Smit

Active 1989–2025

Also published as
Egbert F Smit
254
Papers
47,979
Citations
114
h-index
239
i10-index

Citations

Citations per year for Egbert F. Smit1976: 1 citations1989: 1 citations1990: 1 citations1993: 2 citations1994: 1 citations1995: 1 citations1996: 2 citations1997: 1 citations1998: 1 citations1999: 4 citations2000: 13 citations2001: 21 citations2002: 49 citations2003: 85 citations2004: 154 citations2005: 191 citations2006: 181 citations2007: 178 citations2008: 177 citations2009: 184 citations2010: 166 citations2011: 229 citations2012: 191 citations2013: 305 citations2014: 233 citations2015: 295 citations2016: 354 citations2017: 369 citations2018: 417 citations2019: 1,432 citations2020: 1,896 citations2021: 2,143 citations2022: 1,746 citations2023: 1,471 citations2024: 2,359 citations2025: 1,265 citations2026: 34 citations1977–1988: no citations, so these years are not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,728 citing papers, 20.8% of this breakdownChina: 2,584 citing papers, 11.4% of this breakdownNetherlands: 1,439 citing papers, 6.3% of this breakdownItaly: 1,394 citing papers, 6.1% of this breakdownUnited Kingdom: 1,311 citing papers, 5.8% of this breakdownGermany: 1,239 citing papers, 5.5% of this breakdownFrance: 1,027 citing papers, 4.5% of this breakdownJapan: 942 citing papers, 4.2% of this breakdownSpain: 894 citing papers, 3.9% of this breakdownCanada: 740 citing papers, 3.3% of this breakdownSwitzerland: 623 citing papers, 2.7% of this breakdownSouth Korea: 555 citing papers, 2.4% of this breakdown
0%20.8%Other 23.1%

Institutions

Fields

  • Medicine71.4%
  • Biochemistry, Genetics and Molecular Biology20.7%
  • Immunology and Microbiology1.9%
  • Engineering1.7%
  • Nursing1%
  • Computer Science0.6%
  • Other2.7%

Topics

  • Lung Cancer Treatments and Mutations11%
  • Lung Cancer Research Studies6%
  • Lung Cancer Diagnosis and Treatment5.7%
  • Cancer Immunotherapy and Biomarkers4.5%
  • Cancer Genomics and Diagnostics4.5%
  • Radiomics and Machine Learning in Medical Imaging2.8%
  • Other65.5%

Coauthors

All papers

Open in search
  1. Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

    Authors: Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, Jose M. Pacheco, M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Jänne - New England Journal of Medicine 2021 cited by 980

  2. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Lizza Hendriks, Keith M. Kerr, Jessica Menis, Tony Mok, Ursula Nestle, Antonio Passaro, Solange Peters, David Planchard, Egbert F. Smit, Benjamin Solomon, Giulia Veronesi, Martin Reck - Annals of Oncology 2023 cited by 790

  3. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

    Authors: Krijn K. Dijkstra, Chiara M. Cattaneo, Fleur Weeber, Myriam Chalabi, Joris van de Haar, Lorenzo F. Fanchi, Maarten Slagter, Daphne van der Velden, Sovann Kaing, Sander Kelderman, Nienke van Rooij, Monique E. van Leerdam, Annekatrien Depla, Egbert F. Smit, Koen J. Hartemink, Rosa de Groot, Monika C. Wolkers, Norman Sachs, Pétur Snæbjörnsson, Kim Monkhorst, John B.A.G. Haanen, Hans Clevers, Ton N. Schumacher, Emile E. Voest - Cell 2018 cited by 1,109

  4. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Lizza Hendriks, Keith M. Kerr, Jessica Menis, Tony Mok, Ursula Nestle, Antonio Passaro, Solange Peters, David Planchard, Egbert F. Smit, Benjamin Solomon, Giulia Veronesi, Martin Reck - Annals of Oncology 2023 cited by 580

  5. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: David Planchard, Sanjay Popat, Keith M. Kerr, Silvia Novello, Egbert F. Smit, Corinne Faivre‐Finn, Tony Mok, Martin Reck, Paul E. Van Schil, Matthew D. Hellmann, Solange Peters - Annals of Oncology 2018 cited by 2,299

  6. Long‐term expanding human airway organoids for disease modeling

    Authors: Norman Sachs, Angelos Papaspyropoulos, Domenique D. Zomer-van Ommen, Inha Heo, Lena Böttinger, Dymph Klay, Fleur Weeber, Guizela Huelsz‐Prince, Nino Iakobachvili, Gimano D. Amatngalim, Joep de Ligt, Arne van Hoeck, Natalie Proost, Marco C. Viveen, Anna Lyubimova, Luc Teeven, Sepideh Derakhshan, Jeroen Korving, Harry Begthel, Johanna F. Dekkers, Kuldeep Kumawat, Emilio Ramos, Matthijs FM van Oosterhout, G. Johan A. Offerhaus, Dominique J. Wiener, Eduardo P. Olimpio, Krijn K. Dijkstra, Egbert F. Smit, Maarten van der Linden, Sridevi Jaksani, Marieke van de Ven, Jos Jonkers, Anne C. Rios, Emile E. Voest, Coline HM van Moorsel, Cornelis K. van der Ent, Edwin Cuppen, Alexander van Oudenaarden, Frank E. J. Coenjaerts, Linde Meyaard, Louis Bont, Peter J. Peters, Sander J. Tans, Jeroen S. van Zon, Sylvia F. Boj, Robert G. Vries, Jeffrey M. Beekman, Hans Clevers - The EMBO Journal 2019 cited by 1,080

  7. Pan-cancer whole-genome analyses of metastatic solid tumours

    Authors: Peter Priestley, Jonathan Baber, Martijn P. Lolkema, Neeltje Steeghs, Ewart de Bruijn, Charles Shale, Korneel Duyvesteyn, Susan Haidari, Arne van Hoeck, Wendy Onstenk, Paul Roepman, Mircea Voda, Haiko J. Bloemendal, Vivianne C. G. Tjan‐Heijnen, Carla M.L. van Herpen, Mariëtte Labots, Petronella O. Witteveen, Egbert F. Smit, Stefan Sleijfer, Emile E. Voest, Edwin Cuppen - Nature 2019 cited by 1,213

  8. Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

    Authors: Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist - New England Journal of Medicine 2020 cited by 997

  9. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Authors: Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le - New England Journal of Medicine 2020 cited by 854

  10. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

    Authors: Kōichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Chih‐Hsi S. Kuo, James Chih‐Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne - Journal of Clinical Oncology 2023 cited by 299

  11. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Authors: Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih‐Hsin Yang, Martin Reck, Kiyotaka Yoh, Se‐Hoon Lee, Luis Paz‐Ares, Benjamin Besse, Paolo Bironzo, Dong‐Wan Kim, Melissa L. Johnson, Yi‐Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D. Patel, Egbert F. Smit, Karen L. Reckamp, Qian Dong, Pomy Shrestha, Pang‐Dian Fan, Parul Patel, Andrea Sporchia, David Sternberg, Dalila Sellami, Pasi A. Jänne - Journal of Clinical Oncology 2023 cited by 225

  12. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    Authors: David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson - The Lancet Oncology 2017 cited by 1,367

  13. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

    Authors: Myron G. Best, Nik Sol, Irsan Kooi, Jihane Tannous, Bart A. Westerman, François Rustenburg, Pepijn Schellen, Heleen Verschueren, Edward P. Post, Jan Köster, Bauke Ylstra, Najim Ameziane, Josephine C. Dorsman, Egbert F. Smit, Henk M.W. Verheul, David P. Noske, Jaap C. Reijneveld, R. Jonas A. Nilsson, Bakhos A. Tannous, Pieter Wesseling, Thomas Würdinger - Cancer Cell 2015 cited by 901

  14. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

    Authors: Stefano Trebeschi, Silvia Girolama Drago, Nicolai J. Birkbak, Ieva Kurilova, Adriana Calin, Andrea Delli Pizzi, Ferry Lalezari, Doenja M. J. Lambregts, Maartje W. Rohaan, Chintan Parmar, Elisa A. Rozeman, Koen J. Hartemink, Charles Swanton, John B.A.G. Haanen, Christian U. Blank, Egbert F. Smit, Regina G. H. Beets‐Tan, Hugo J.W.L. Aerts - Annals of Oncology 2019 cited by 558

  15. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Authors: Martin Peifer, Lynnette Fernandez‐Cuesta, Martin L. Sos, Julie George, Danila Seidel, Lawryn H. Kasper, Dennis Plenker, Frauke Leenders, Ruping Sun, Thomas Zander, Roopika Menon, Mirjam Koker, Ilona Dahmen, Christian Müller, Vincenzo Di Cerbo, Hans‐Ulrich Schildhaus, Janine Altmüller, Ingelore Baessmann, Christian Becker, Bram De Wilde, Jo Vandesompele, Diana Böhm, Sascha Ansén, Franziska Gabler, Ines Wilkening, Stefanie Heynck, Johannes M. Heuckmann, Xin Lü, Scott L. Carter, Kristian Cibulskis, Shantanu Banerji, Gad Getz, Kwon-Sik Park, Daniel Rauh, Christian Grütter, Matthias Fischer, Laura Pasqualucci, Gavin Wright, Zoe Wainer, Prudence A. Russell, Iver Petersen, Yuan Chen, Erich Stoelben, Corinna Ludwig, Philipp A. Schnabel, Hans Hoffmann, Thomas Muley, Michael Brockmann, Walburga Engel-Riedel, Lucia Anna Muscarella, Vito Michele Fazio, Harry J.M. Groen, Wim Timens, Hannie Sietsma, Erik Thunnissen, Egbert F. Smit, Daniëlle A.M. Heideman, Peter J.F. Snijders, Federico Cappuzzo, Claudia Ligorio, Stefania Damiani, John K. Field, Steinar Solberg, Odd Terje Brustugun, Marius Lund‐Iversen, Jörg Sänger, Joachim H. Clement, Alex Soltermann, Holger Moch, Walter Weder, Benjamin Solomon, Jean‐Charles Soria, Pierre Validire, Benjamin Besse, Élisabeth Brambilla, Christian Brambilla, Sylvie Lantuéjoul, Philippe Lorimier, Peter M. Schneider, Michael Hallek, William Pao, Matthew Meyerson, Julien Sage, Jay Shendure, Robert C. Schneider, Reinhard Büttner, Jürgen Wolf, Peter Nürnberg, Sven Perner, Lukas C. Heukamp, Paul K. Brindle, Stefan A. Haas, Roman K. Thomas - Nature Genetics 2012 cited by 1,418

  16. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

    Authors: Egbert F. Smit, Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares, Jose M. Pacheco, Bob T. Li, David Planchard, Christina S. Baik, Yasushi Goto, Haruyasu Murakami, Andreas Saltos, Kaline Pereira, Ayumi Taguchi, Yingkai Cheng, Qi Yan, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne - The Lancet Oncology 2024 cited by 156

  17. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

    Authors: Charles A. Powell, Shanu Modi, Hiroji Iwata, Shunji Takahashi, Egbert F. Smit, Salvatore Siena, D.-Y. Chang, E. Macpherson, A. Qin, Jasmeet Singh, Corina Taitt, Norah J. Shire, D. Ross Camidge - ESMO Open 2022 cited by 231

  18. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

    Authors: Gregory J. Riely, Egbert F. Smit, Myung‐Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne S. Tsao, Melissa L. Johnson, Francesco Gelsomino, Raymond M. Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo‐Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith D. Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson - Journal of Clinical Oncology 2023 cited by 114

  19. Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine

    Authors: Krijn K. Dijkstra, Kim Monkhorst, Luuk J. Schipper, Koen J. Hartemink, Egbert F. Smit, Sovann Kaing, Rosa de Groot, Monika C. Wolkers, Hans Clevers, Edwin Cuppen, Emile E. Voest - Cell Reports 2020 cited by 256

  20. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

    Authors: Anna-Larissa N. Niemeijer, David Leung, Marc C. Huisman, Idris Bahce, Otto S. Hoekstra, Guus A.M.S. van Dongen, Ronald Boellaard, Shuyan Du, Wendy Hayes, Ralph C. Smith, Albert D. Windhorst, N. Harry Hendrikse, Alex J. Poot, Daniëlle J. Vugts, Erik Thunnissen, Paul E. Morin, Daša Lipovšek, David J. Donnelly, Samuel J. Bonacorsi, Lauren Velasquez, Tanja D. de Gruijl, Egbert F. Smit, Adrianus J. de Langen - Nature Communications 2018 cited by 483

  21. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

    Authors: Daphne van der Velden, Louisa R. Hoes, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Erik van Werkhoven, Paul Roepman, Richard L. Schilsky, Wendy W.J. de Leng, Alwin D. R. Huitema, Bastiaan Nuijen, Petra M. Nederlof, Carla M.L. van Herpen, Derk Jan A. de Groot, Lot A. Devriese, Ann Hoeben, Maja J.A. de Jonge, Myriam Chalabi, Egbert F. Smit, Adrianus J. de Langen, Niven Mehra, Mariëtte Labots, Ellen Kapiteijn, Stefan Sleijfer, Edwin Cuppen, Henk M.W. Verheul, Hans Gelderblom, Emile E. Voest - Nature 2019 cited by 269

  22. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

    Authors: Joe Y. Chang, Suresh Senan, Marinus A. Paul, Reza J. Mehran, Alexander V. Louie, Peter Balter, Harry J.M. Groen, Stephen E. McRae, Joachim Widder, Lei Feng, Ben E.E.M. van den Borne, Mark F. Munsell, Coen Hurkmans, Donald A. Berry, Erik van Werkhoven, John J. Kresl, Anne‐Marie C. Dingemans, Omar Thanoon Dawood, Cornelis J.A. Haasbeek, L.Steven Carpenter, Katrien De Jaeger, Ritsuko Komaki, Ben J. Slotman, Egbert F. Smit, Jack A. Roth - The Lancet Oncology 2015 cited by 1,459

  23. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets

    Authors: Myron G. Best, Nik Sol, Sjors G. J. G. In ‘t Veld, Adrienne Vancura, Mirte Muller, Anna-Larissa N. Niemeijer, Aniko V. Fejes, Lee-Ann Tjon Kon Fat, Anna E. Huis in ‘t Veld, Cyra E Leurs, Tessa Y. Le Large, Laura L. Meijer, Irsan Kooi, François Rustenburg, Pepijn Schellen, Heleen Verschueren, Edward P. Post, Laurine E. Wedekind, Jillian Wilhelmina Paulina Bracht, Michelle Esenkbrink, Leon J. Wils, Francesca Favaro, Jilian D. Schoonhoven, Jihane Tannous, Hanne Meijers‐Heijboer, Geert Kazemier, Elisa Giovannetti, Jaap C. Reijneveld, Sander Idema, Joep Killestein, Michal Heger, Saskia C.A. de Jager, Rolf T. Urbanus, Imo E. Hoefer, Gerard Pasterkamp, Christine Mannhalter, Jose Gomez‐Arroyo, Harm Jan Bogaard, David P. Noske, W. Peter Vandertop, Daan van den Broek, Bauke Ylstra, R. Jonas A. Nilsson, Pieter Wesseling, Niki Karachaliou, Rafael Rosell, Elizabeth Lee-Lewandrowski, Kent Lewandrowski, Bakhos A. Tannous, Adrianus J. de Langen, Egbert F. Smit, Michel M. van den Heuvel, Thomas Würdinger - Cancer Cell 2017 cited by 333

  24. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    Authors: Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F. Smit, Alberto Chiappori, M.E. Olmedo, Ildikó Horváth, Christian Grohé, Anna F. Farago, José Antonio López-Vilariño, Martín Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Enric Carcereny, Jaromı́r Roubec, Konstantinos Syrigos, Gregory Lo, I. Barneto, Anthony Pope, Amparo Martínez Sánchez, Joseph Kattan, Paul Zarogoulidis, Cornelius F. Waller, Helge Bischoff, Óscar Juan, Niels Reinmuth, Manuel Dómine, Luis Paz‐Ares - The Lancet Respiratory Medicine 2022 cited by 120